Thank to our member, we now have an information about the good response to another PD-L1 immunotherapy drug on a market - TECENTRIQ (atezolizumab) by Genentech, Roche's subsidiary.
The patient Auz from Toronto - Dx May 2015 at 19 yo is participating in a clinical trial ClinicalTrials.gov Identifier: NCT02458638
view here:
https://clinicaltrials.gov/ct2/show/NCT02458638
reposted from here:
viewtopic.php?f=4&t=1086&p=9907#p9907
It is now approved for the advanced urothelial carcinoma (mUC) or non-small cell lung cancer (NSCLC) in US, but It could probably be prescribed for ASPS off label if there are no other treatment options available and based on a response our patient is having.
It is still preferable to get the drug on a trial versus off label if possible so the response is properly documented and the patient gets proper side effects care as they might be not that well known by now.
Please post here any personal experiences if getting this drug on off label basis.
TECENTRIQ can be prescr. off label now
Pseudoprogression of CNS metastatic disease of alveolar soft part sarcoma during anti-PDL1 treatment☆☆☆
Abstract
Immune checkpoint inhibitors are increasingly used in treatment of metastatic renal cell carcinoma, melanoma, and nonsmall cell lung cancer, as well as in clinical trials for novel targets. We present a pediatric patient with metastatic alveolar soft part sarcoma who was treated with MPDL3280 (Atezolizumab), a monoclonal anti-programmed death ligand-1 antibody. Imaging results for the patient suggested disease progression of multiple brain metastases with stable systemic disease. The patient met response evaluation criteria in solid tumors (RECIST) criteria of progression of disease and was removed from treatment with MPDL3280. Subsequent surgical resection of the brain lesions revealed nonviable tumor with extensive lymphocytic infiltrates consistent with pseudoprogression. This case report adds to a growing number of reports that question reliance on RECIST criteria and suggest need for further refinement of RECIST or irRECIST during immune checkpoint inhibitor treatment for central nervous system metastatic lesions.
Keywords: Pseudoprogression, PDL1, Alveolar soft part sarcoma
https://www.ncbi.nlm.nih.gov/pmc/articl ... po=44.2308
Immune checkpoint inhibitors are increasingly used in treatment of metastatic renal cell carcinoma, melanoma, and nonsmall cell lung cancer, as well as in clinical trials for novel targets. We present a pediatric patient with metastatic alveolar soft part sarcoma who was treated with MPDL3280 (Atezolizumab), a monoclonal anti-programmed death ligand-1 antibody. Imaging results for the patient suggested disease progression of multiple brain metastases with stable systemic disease. The patient met response evaluation criteria in solid tumors (RECIST) criteria of progression of disease and was removed from treatment with MPDL3280. Subsequent surgical resection of the brain lesions revealed nonviable tumor with extensive lymphocytic infiltrates consistent with pseudoprogression. This case report adds to a growing number of reports that question reliance on RECIST criteria and suggest need for further refinement of RECIST or irRECIST during immune checkpoint inhibitor treatment for central nervous system metastatic lesions.
Keywords: Pseudoprogression, PDL1, Alveolar soft part sarcoma
https://www.ncbi.nlm.nih.gov/pmc/articl ... po=44.2308
Debbie